Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
26-29 March, 2025
Not Confirmed
Not Confirmed
27-29 March, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
26-29 March, 2025
Industry Trade Show
Not Confirmed
27-29 March, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
12 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/12/2944919/0/en/Press-Release-Sanofi-RadioMedix-and-Orano-Med-announce-licensing-agreement-on-next-generation-radioligand-medicine-for-rare-cancers.html
12 Feb 2024
// BUSINESSWIRE
15 Feb 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/02/15/2608809/0/en/RadioMedix-Inc-Announces-the-Acquisition-of-its-225Ac-PSMA-I-T-program-a-Targeted-Alpha-Therapy-TAT-for-Metastatic-Castration-Resistant-Prostate-Cancer-by-Fusion-Pharmaceuticals-In.html
15 Nov 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/11/15/2555865/0/en/RadioMedix-and-Vect-Horus-announce-first-dosing-of-Glioblastoma-Multiforme-and-Pancreatic-ductal-adenocarcinoma-patients-with-68Ga-RMX-VH.html
07 Oct 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/10/07/2530586/0/en/RadioMedix-announces-a-40-million-Series-A-financing-for-the-advancement-of-novel-Targeted-Alpha-Therapy-platform-and-diagnostic-companion-radiopharmaceuticals-to-address-unmet-nee.html
03 Jan 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/01/03/2360157/0/en/Radiomedix-and-Orano-Med-Announce-the-Initiation-of-the-Phase-II-Multi-Center-Clinical-Trial-of-Alphamedix-for-Targeted-Alpha-Emitter-Therapy-of-Neuroendocrine-Cancers.html
ABOUT THIS PAGE